NGVTIngevity Corporation

$69.86+24% 1Y

$69.86

$46.2052 weeks$77.87

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though at the top of its own P/E range.

1 to watch, 2 without data

What the price assumes~+3% a yearderived · Jun 30, 2026

Priced for ~3% a year FCF growth. Moderate growth expectations are priced in.

Vs its own P/E rangedearer than 87% of its own historyderived

Expensive vs its own history: P/E 46.6 vs a 21.1 median over 31 quarters (+121% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 85% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Ingevity Corporation trades at 46.6× earnings against 29.4× for the median Specialty Chemicals name, more expensive than its own group.

46.6

Trailing P/E · Specialty Chemicals median 29.4 · 1.58× the median: the market pays up for this one

Price / sales: 2.22
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 6.0%
Free cash flow yield · Specialty Chemicals median 4.7%
Growth the price implies: +3.2%
Growth the price implies · The price pays for +3.2% free cash flow growth a year for a decade; the business has delivered +8.9% a year over the last three.